Neurology

Back to articles

Fingolimod and dimethyl fumarate appear to have similar efficacy for MS

KEY POINT

Use of fingolimod (Gilenya—Novartis) or delayed-release dimethyl fumarate (Tecfidera—Biogen) for patients with relapsing-remitting multiple sclerosis (RRMS) appears to have similar efficacy for treatment-naive patients, but use of fingolimod appears to have superior efficacy in treatment-experienced patients, according to results of an observational study published in Neurology.

SOURCES

Prosperini L, et al. Fingolimod vs dimethyl fumarate in multiple sclerosis. Neurology. 2018;[Epub ahead of print].